LENZ Therapeutics (LENZ) Revenue (2025 - 2026)

LENZ Therapeutics (LENZ) reported Revenue of $1.9 million for Q1 2026, up 115.21% quarter-over-quarter from -$12.5 million in Q4 2025.

LENZ Therapeutics (LENZ) Revenue (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has 2 years of Revenue data on file, last reported at $1.9 million in Q1 2026.

Revenue for Q1 2026 came in at $1.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (changed N/A YoY), and the FY2025 annual result was $5.0 million, changed N/A from the prior year.
Revenue rose to $1.9 million in Q1 2026 per LENZ's latest filing, from -$12.5 million in the prior quarter.
Over five years, Revenue peaked at $12.5 million in Q3 2025 and troughed at -$12.5 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	5.21 Mn
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	306.30 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.99 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	LENZ Therapeutics	192.19 Mn	192.19 Mn	825,000.00	1.90 Mn

Download Data